Phase 3 cancer immunotherapy company Cel-Sci (NYSE:CVM) announced today that it raised approximately $10 million through the exercise of warrants.
The Vienna, Va.-based company plans to use the funds to complete the expansion of its Multikine cancer immunotherapy manufacturing facility near Baltimore in anticipation of a biologics license application (BLA) submission and the subsequent effort to receive marketing approval, according to a news release.
Cel-Sci’s Multikine is an immunotherapeutic agent in development to become a first-line neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck, and potentially as a treatment for cervical dysplasia or peri-anal warts in HIV/HPV co-infected patients.
The company also develops Leaps, a T-cell modulation, peptide epitope delivery system designed to synthesize proprietary peptide immunogens.